---
title: "Sat Kartar Life Ltd (SATKARTAR) — Share Price, Financials & Analysis"
symbol: "SATKARTAR"
company: "Sat Kartar Life Ltd"
canonical: "https://tapetide.com/stocks/SATKARTAR"
isin: "INE0NB801022"
nse_symbol: "SATKARTAR"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
market_cap_cr: 225.87
generated_at: "2026-09-13T19:38:31.046Z"
---

# Sat Kartar Life Ltd (SATKARTAR)

Canonical page: https://tapetide.com/stocks/SATKARTAR

## Company

- **NSE Symbol:** SATKARTAR
- **ISIN:** INE0NB801022
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-01-17
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** satkartar.in

## About

Incorporated in June 2012, Sat Kartar Shopping Limited is an Ayurveda healthcare company that delivers natural wellness solutions for therapeutic and lifestyle products.[1]

## Latest Price

- **Price:** ₹145.2
- **Change:** +14 (+10.67%)
- **Open:** ₹137
- **Day High:** ₹148
- **Day Low:** ₹135.25
- **Previous Close:** ₹131.2
- **Volume:** 164800
- **As Of:** 2026-09-11T09:59:11+00:00

## Key Fundamentals

Observed at 2026-09-11T04:45:22.830776Z.

- **Market Cap:** ₹225.87 Cr
- **Classification:** SME
- **P/E (reported):** 12.1
- **Book Value:** ₹43.34
- **Price to Book:** 3.03
- **Dividend Yield:** 0.53%
- **ROE:** 25.3%
- **ROCE:** 34.31%
- **Debt to Equity:** 0.03
- **Revenue (yearly):** ₹203.1 Cr
- **Net Income:** ₹17.1 Cr
- **EBITDA:** ₹27.1 Cr
- **52-Week High:** ₹219.8
- **52-Week Low:** ₹110.3
- **RSI (14):** 56.3

## Tapetide Score

- **Score:** 63 / 100
- **Score date:** 2026-09-04
- **Archetype:** Out of Favour
- **What it means:** Financially sound, yet the market is not rewarding it. Cases like this usually need a specific reason the pessimism is misplaced, and patience for that reason to play out.
- **Pillar profile:** Quality: Good · Valuation: Fair · Momentum: Falling
- **Percentile:** 94.2 (of 4473 scored stocks)
- **Confidence:** 86%
- **Data coverage:** 71%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 83.48 | 9% |
| growth | 64.45 | 9% |
| momentum | 13.93 | 12% |
| ownership | 70.14 | 24% |
| quality | 74.45 | 22% |
| valuation | 59.8 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 33.0%

### Weaknesses

- Working capital days have increased from 28.3 days to 60.9 days

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | 109.47% | -99.91% | -99.69% |
| ebitda margin growth | 45.74% | — | — |
| net income growth | 74.49% | 85% | — |
| revenue growth | 24.07% | 33% | — |
| roce | 34.02% | — | — |
| roe | 32.74% | — | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 75 | 76 | 87 | 88 | 105 |
| Expenses | 69 | 70 | 79 | 78 | 91 |
| Operating Profit | 6 | 6 | 9 | 10 | 14 |
| OPM % | 8 | 7 | 10 | 12 | 14 |
| Other Income | 0 | 0 | 1 | 2 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 2 |
| Profit before tax | 5 | 5 | 8 | 11 | 13 |
| Tax % | 27 | 25 | 25 | 26 | 26 |
| Net Profit | 4 | 4 | 6 | 8 | 9 |
| EPS in Rs | 13.29 | 3.3 | 3.8 | 4.95 | 6.01 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 52 | 83 | 128 | 163 | 194 |
| Expenses | 49 | 78 | 118 | 149 | 169 |
| Operating Profit | 3 | 5 | 10 | 14 | 25 |
| OPM % | 5 | 6 | 8 | 9 | 13 |
| Other Income | 0 | 0 | 0 | 1 | 2 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 3 |
| Profit before tax | 2 | 3 | 9 | 13 | 23 |
| Tax % | 7 | 27 | 27 | 25 | 26 |
| Net Profit | 1 | 3 | 6 | 10 | 17 |
| EPS in Rs | 1.99 | 3.59 | 22.54 | 6.24 | 10.96 |
| Dividend Payout % | 0 | 0 | 3 | 11 | 6 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.7 | 0.7 | 3 | 16 | 16 |
| Reserves | 0 | 3 | 7 | 36 | 52 |
| Borrowings | 8 | 4 | 2 | 6 | 2 |
| Other Liabilities | 3 | 8 | 11 | 7 | 14 |
| Total Liabilities | 12 | 15 | 22 | 65 | 84 |
| Fixed Assets | 5 | 4 | 8 | 6 | 11 |
| CWIP | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 0 | 1 |
| Other Assets | 8 | 11 | 14 | 58 | 71 |
| Total Assets | 12 | 15 | 22 | 65 | 84 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | — | — | 7 | -5 | 0 |
| Cash from Investing Activity | — | — | -3 | 0 | -9 |
| Cash from Financing Activity | — | — | -3 | 34 | -1 |
| Net Cash Flow | — | — | 2 | 28 | -9 |
| Free Cash Flow | — | — | 7 | -10 | -7 |
| CFO/OP | — | — | 98 | -13 | 26 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 1 | 0 | 7 | 13 | 26 |
| Inventory Days | 31 | 25 | 23 | 185 | 258 |
| Days Payable | 165 | 226 | 237 | 170 | 293 |
| Cash Conversion Cycle | -134 | -200 | -208 | 29 | -9 |
| Working Capital Days | 1 | -14 | -7 | 31 | 61 |
| ROCE % | — | 50 | 98 | 40 | 36 |

## Shareholding Pattern

### Quarterly

| Category | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Promoters | 63.34% | 63.43% | 63.62% |
| FIIs | 6.31% | 0% | 0.13% |
| DIIs | 0% | 0% | 2.26% |
| Government | 0% | 0% | 0% |
| Public | 17.81% | 24.41% | 27.29% |
| Others | 12.54% | 12.16% | 6.71% |
| No. of Shareholders | 425 | 717 | 846 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 9 / 6 / 4

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 122.48 | Buy |
| EMA (10) | 126.24 | Buy |
| SMA (20) | 124.19 | Buy |
| EMA (20) | 125.32 | Buy |
| SMA (50) | 127.84 | Buy |
| EMA (50) | 131.12 | Buy |
| SMA (100) | 151.47 | Sell |
| EMA (100) | 141.69 | Buy |
| SMA (200) | 155.06 | Sell |
| EMA (200) | 151.51 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 65.42 | Neutral |
| MACD (12,26,9) | -0.1 | Buy |
| Stochastic (14,3,3) | 47.22 | Neutral |
| ADX (14) | 21.61 | Neutral |
| Williams %R (14) | -20.14 | Neutral |
| ATR (14) | 8.71 | High Volatility |
| ROC (12) | 7 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 59.1 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 May 2026 - Submitted H2/FY26 earnings call transcript; revenue rose 23%, EBITDA 73%, PAT 74%, with hospital expansion plans. | [Analysts/Institutional Investor Meet/Con. Call Updates 9 May 2026 - Submitted H2/FY26 earnings call transcript; revenue rose 23%, EBITDA 73%, PAT 74%, with hospital expansion plans.](https://nsearchives.nseindia.com/corporate/SATKARTAR_09052026194024_Transcript_of_Earnings_con_call.pdf) |
| 9 May 2026 - NSE granted in-principle approval for 50,400 equity shares and 27,74,400 shares from warrant conversion. | [Updates 9 May 2026 - NSE granted in-principle approval for 50,400 equity shares and 27,74,400 shares from warrant conversion.](https://nsearchives.nseindia.com/corporate/SATKARTAR_09052026134734_Intimation_of_preferential_issue_approval.pdf) |
| 8 May 2026 - Exchange has sought clarification from Sat Kartar Life Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. … | [Clarification - Financial Results 8 May 2026 - Exchange has sought clarification from Sat Kartar Life Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (LODR) Regulations, 2015. …](https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=SATKARTAR&tabIndex=sme) |
| 8 May 2026 - Company adopts curated spiritual and wellness products business; investment amount remains undecided. | [Adoption of new line(s) of business 8 May 2026 - Company adopts curated spiritual and wellness products business; investment amount remains undecided.](https://nsearchives.nseindia.com/corporate/SATKARTAR_08052026175209_Intimation_of_New_line_of_businesss_.pdf) |
| 8 July 2026 - Company claims exemption from corporate governance report for quarter ended 30 June 2026. | [Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter 8 July 2026 - Company claims exemption from corporate governance report for quarter ended 30 June 2026.](https://nsearchives.nseindia.com/corporate/SATKARTAR_08072026134229_Non_applicability_of_corporate_governance.pdf) |
| 8 April 2026 - Company declares Annual Secretarial Compliance Report not applicable for FY ended 31.03.2026 on NSE SME platform. | [Updates 8 April 2026 - Company declares Annual Secretarial Compliance Report not applicable for FY ended 31.03.2026 on NSE SME platform.](https://nsearchives.nseindia.com/corporate/SATKARTAR_08042026104834_24A_non_applicability.pdf) |
| 7 May 2026 - Audio recording of earnings conference call for FY26 and H2FY26 available on website. | [Analysts/Institutional Investor Meet/Con. Call Updates 7 May 2026 - Audio recording of earnings conference call for FY26 and H2FY26 available on website.](https://nsearchives.nseindia.com/corporate/SATKARTAR_07052026195025_link_of_Audio_Call.pdf) |
| 7 July 2026 - NSE granted trading approval for 50,400 preferential shares; admitted for trading from 7 July 2026, locked in till 29 Jan 2027. | [Granting/withdrawal/surrender/cancellation/suspension of key licenses/ regulatory approvals 7 July 2026 - NSE granted trading approval for 50,400 preferential shares; admitted for trading from 7 July 2026, locked in till 29 Jan 2027.](https://nsearchives.nseindia.com/corporate/SATKARTAR_07072026182109_Intimation_of_receipt_of_trading_approval.pdf) |
| 7 April 2026 - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 7 April 2026 - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026.](https://nsearchives.nseindia.com/corporate/SATKARTAR_07042026151556_Certificate_under_regulation_74_5_.pdf) |
| 7 April 2026 - Promoter declares no additional encumbrance on shares for FY ended March 31, 2026. | [Disclosure under SEBI Takeover Regulations 7 April 2026 - Promoter declares no additional encumbrance on shares for FY ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/team_sandeshc_06042026133822_Encumbrance.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30162_SATKARTAR_2025_2026_A_13012504_03082026200824.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_27330_SATKARTAR_2024_2025_A_07082025164301.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2025 | [Concall - Oct 2025](https://nsearchives.nseindia.com/corporate/SATKARTAR_30102025200818_Investorspresentation30102025.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://nsearchives.nseindia.com/corporate/SATKARTAR_03112025184857_transcript01112025.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://nsearchives.nseindia.com/corporate/SATKARTAR_03112025183508_Satkartar__transcript.pdf) |
| May 2025 | [Concall - May 2025](https://nsearchives.nseindia.com/corporate/SATKARTAR_21052025161601_TranscriptEarningConcall_1.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:38:31.046Z.